Ungrouped (n = 110) | % | Clustered (n = 85) | % | Univariate logistic regression | ||||
---|---|---|---|---|---|---|---|---|
OR | 95% lower | 95% upper | P value | |||||
Age | ||||||||
> 50 | 18 | 16.4 | 6 | 7.1 | REF | |||
30–50 | 51 | 46.4 | 44 | 51.8 | 2.6 | 0.9 | 7.1 | 0.06 |
< 30 | 34 | 30.9 | 30 | 35.3 | 2.6 | 0.9 | 7.5 | 0.07 |
Unknown | 7 | 6.4 | 5 | 5.9 | 2.1 | 0.5 | 9.4 | 0.31 |
Gender | ||||||||
Female | 41 | 37.3 | 37 | 43.5 | REF | |||
Male | 66 | 60 | 46 | 54.1 | 0.8 | 0.4 | 1.4 | 0.39 |
Unknown | 3 | 2.7 | 2 | 2.4 | 0.7 | 0.1 | 4.7 | 0.75 |
HIV status | ||||||||
Negative | 50 | 45.5 | 51 | 60 | REF | |||
Positive | 33 | 30 | 20 | 23.5 | 0.6 | 0.3 | 1.2 | 0.13 |
Unknown | 27 | 24.5 | 14 | 16.5 | 0.5 | 0.2 | 1.1 | 0.08 |
Lineage | ||||||||
Others | 7 | 6.4 | 10 | 11.8 | REF | |||
L4.X | 49 | 44.5 | 26 | 30.6 | 0.4 | 0.1 | 1.1 | 0.07 |
L4.6 | 54 | 49.1 | 49 | 57.6 | 0.6 | 0.2 | 1.8 | 0.39 |
Genotypic resistances (n) | 1.7 (mean) | 2.4 (mean) | 1.7 | 1.3 | 2.3 | 6.64E−05 | ||
(per unit increase) | ||||||||
Compensatory mutation | ||||||||
No | 85 | 77.3 | 53 | 62.4 | REF | |||
Yes | 25 | 22.7 | 32 | 37.6 | 2.1 | 1.1 | 3.8 | 0.02 |
High dose isoniazid | ||||||||
Susceptible | 39 | 35.5 | 5 | 5.9 | REF | |||
Resistant | 71 | 64.5 | 80 | 94.1 | 8.8 | 3.3 | 23.5 | 1.53E−05 |
Ethambutol | ||||||||
Susceptible | 62 | 56.4 | 22 | 25.9 | REF | |||
Resistant | 48 | 43.6 | 63 | 74.1 | 3.7 | 2 | 6.8 | 3.02E−05 |
Pyrazinamide | ||||||||
Susceptible | 70 | 63.6 | 41 | 48.2 | REF | |||
Resistant | 40 | 36.4 | 44 | 51.8 | 1.8 | 1.1 | 3.3 | 0.03 |
Prothionamide | ||||||||
Susceptible | 87 | 79.1 | 69 | 81.2 | REF | |||
Resistant | 23 | 20.9 | 16 | 18.8 | 0.9 | 0.4 | 1.8 | 0.72 |